SPOTLIGHT -
Pittsburgh-IOP-lowering products evaluated in the "real-world" setting of a clinical practice can provide valuable information for practitioners, according to Evan B. Dreyer, MD, PhD.
Novartis finalizes divestment of ‘front of eye’ ophthalmology assets
EyePod: Week in Review - September 24, 2023
Outlook Therapeutics requests Type A meeting with FDA
EyePod: Transforming the MIGS pipeline into clinical reality
BLOG: MicroPulse TLT for patients who struggle with drops
Digital healthcare startup eyecbetter kicks off Regulation C crowdfunding campaign on StartEngine